Department of Medical Oncology, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.
Department of Clinical Research, Max Institute of Cancer Care, Max Super Specialty Hospital, New Delhi, India.
J Cancer Res Ther. 2021 Apr-Jun;17(2):389-392. doi: 10.4103/jcrt.JCRT_342_19.
The addition of docetaxel or abiraterone to androgen deprivation therapy (ADT) achieves superior survival outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) in predominantly Western population. We sought to evaluate the treatment outcomes of adding docetaxel or abiraterone to ADT in Indian population.
We reviewed the medical records of ninety patients with newly diagnosed mHSPC who received treatment between January 2015 and June 2018. Patients received ADT alone or ADT + docetaxel or ADT + abiraterone as initial treatment. Monthly clinical evaluation and prostate-specific antigen (PSA) measurement were done. Outcome measures analyzed included PSA decline <90%, serological complete response (sCR) (PSA < 0.2 ng/ml), and progression to CRPC. Outcome variable was compared using Fisher's exact test.
Patients received ADT alone (n = 37) or ADT + docetaxel (n = 31) or ADT + abiraterone (n = 22). The median age was 67.5 years (range, 41-87 years) and the median PSA was 88.5 ng/ml (range, 1.12-4000). PSA decline <90% was seen in 22 (73%), 24 (86%), and 17 (94%) patients in the ADT alone, ADT + docetaxel, and ADT + abiraterone groups. sCR was achieved in 5 (17%), 10 (36%), and 9 (50%) patients in the ADT alone, ADT + docetaxel, and ADT + abiraterone groups. Progression to CRPC was observed in 18 (60%), 11 (39%), and 2 (11%) patients in the ADT alone, ADT + docetaxel, and ADT + abiraterone groups.
The addition of docetaxel or abiraterone to ADT achieves a deeper serological response and reduces progression to CRPC compared to ADT alone in mHSPC patients of Indian origin. Longer follow-up is required to comment on overall survival and also to determine which combination (ADT + docetaxel or ADT + abiraterone) is superior to others, if at all.
在主要为西方人群的转移性激素敏感前列腺癌（mHSPC）中，多西他赛或阿比特龙联合雄激素剥夺治疗（ADT）可显著提高生存率。我们旨在评估在印度人群中添加多西他赛或阿比特龙治疗 mHSPC 的治疗效果。
我们回顾了 2015 年 1 月至 2018 年 6 月期间接受治疗的 90 例新诊断为 mHSPC 的患者的病历。患者接受 ADT 单药治疗或 ADT+多西他赛或 ADT+阿比特龙作为初始治疗。每月进行临床评估和前列腺特异性抗原（PSA）检测。分析的结局指标包括 PSA 下降<90%、血清学完全缓解（sCR）（PSA<0.2ng/ml）和进展为 CRPC。使用 Fisher 确切检验比较结局变量。
患者接受 ADT 单药治疗（n=37）或 ADT+多西他赛（n=31）或 ADT+阿比特龙（n=22）治疗。中位年龄为 67.5 岁（范围，41-87 岁），中位 PSA 为 88.5ng/ml（范围，1.12-4000）。ADT 单药、ADT+多西他赛和 ADT+阿比特龙组中，PSA 下降<90%的患者分别为 22 例（73%）、24 例（86%）和 17 例（94%）。ADT 单药、ADT+多西他赛和 ADT+阿比特龙组中达到 sCR 的患者分别为 5 例（17%）、10 例（36%）和 9 例（50%）。ADT 单药、ADT+多西他赛和 ADT+阿比特龙组中进展为 CRPC 的患者分别为 18 例（60%）、11 例（39%）和 2 例（11%）。
与 ADT 单药治疗相比，在印度起源的 mHSPC 患者中，多西他赛或阿比特龙联合 ADT 治疗可获得更深的血清学缓解，并降低进展为 CRPC 的风险。需要更长时间的随访才能对总体生存率进行评价，也才能确定哪种联合治疗（ADT+多西他赛或 ADT+阿比特龙）更优，如果有的话。
